Latest from SCCA

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses patient eligibility criteria for transplant in multiple myeloma.
Celestia S. Higano, MD, discusses the outcomes of the GETUG-AFU 16 and its impact on current practices for prostate cancer.
Evan Y. Yu, MD, discusses the rationale behind the KEYNOTE-365 trial, looking at pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington School of Medicine, and attending physician, Seattle Cancer Care Alliance, discusses fixed durations of treatment in chronic lymphocytic leukemia (CLL).
Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine and hematologist/oncologist at Seattle Cancer Care Alliance, discusses treatment strategies for patients with transplant-eligible and -ineligible multiple myeloma.
Mary-Elizabeth Percival, MD, discusses advances and challenges with targeted agents in acute myeloid leukemia and remaining questions in the field.
Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the FDA approval of avatrombopag in immune thrombocytopenia (ITP).
Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.
Publication Bottom Border
Border Publication
x